Disease-related costs published in the Middle East and North Africa Region: systematic review and analysis of transferability
Abstract Background In the Middle East and North Africa (MENA) the scarcity of local cost
data is a key barrier to conducting health economic evaluations. We systematically reviewed …
data is a key barrier to conducting health economic evaluations. We systematically reviewed …
[图书][B] Priority medicines for Europe and the world
W Kaplan, R Laing - 2004 - strama.se
The mention of specific companies or of certain manufacturers' products does not imply that
they are endorsed or recommended by the World Health Organization in preference to …
they are endorsed or recommended by the World Health Organization in preference to …
Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data
MSM van Mourik, A Cameron, M Ewen… - BMC Cardiovascular …, 2010 - Springer
Background The global burden of cardiovascular disease (CVD) continues to rise.
Successful treatment of CVD requires adequate pharmaceutical management. The aim was …
Successful treatment of CVD requires adequate pharmaceutical management. The aim was …
[HTML][HTML] A path to eradication of hepatitis C in low-and middle-income countries
CS Graham, T Swan - Antiviral research, 2015 - Elsevier
We are entering a new era in the treatment of hepatitis C virus (HCV) infection and almost all
patient groups in high-income countries have the potential to be cured with all-oral, highly …
patient groups in high-income countries have the potential to be cured with all-oral, highly …
[HTML][HTML] Payers' experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and …
Institutional payers for pharmaceuticals worldwide appear to be increasingly negotiating
confidential discounts off of the official list price of pharmaceuticals purchased in the …
confidential discounts off of the official list price of pharmaceuticals purchased in the …
A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries
Background Tiered pricing-the concept of selling drugs and vaccines in developing
countries at prices systematically lower than in industrialized countries-has received …
countries at prices systematically lower than in industrialized countries-has received …
The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries
ABSTRACT Introduction Lower-income European countries have a worse health status and
less funds for health care compared to Western Europe. Despite their limited human and …
less funds for health care compared to Western Europe. Despite their limited human and …
Ebola vaccine development plan: ethics, concerns and proposed measures
Background The global interest in developing therapies for Ebola infection management
and its prevention is laudable. However the plan to conduct an emergency immunization …
and its prevention is laudable. However the plan to conduct an emergency immunization …
[HTML][HTML] Value-based tiered pricing for universal health coverage: an idea worth revisiting
K Chalkidou, K Claxton, R Silverman… - Gates open …, 2020 - ncbi.nlm.nih.gov
The pricing of medicines and health products ranks among the most hotly debated topics in
health policy, generating controversy in richer and poorer markets alike. Creating the right …
health policy, generating controversy in richer and poorer markets alike. Creating the right …
Price differentiation and transparency in the global pharmaceutical marketplace
DB Ridley - Pharmacoeconomics, 2005 - Springer
Pharmaceutical manufacturers have increased the availability of their products and
sometimes increased their own financial returns by charging lower prices outside of the US …
sometimes increased their own financial returns by charging lower prices outside of the US …